image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Exhibition 
 Contact Us 
 Personal page 
 Photo and Film Festival 
       XXVI Annual Congress of the Iranian Society of Ophthalmology        بـیــست و ششمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) Combined with Bevacizumab versus Bevacizumab Monotherapy for Diabetic Macular Edema; a Randomized Clinical Trial
Author(s): Ramin Nourinia, Hamid Ahmadieh, Ali Hafezi-moghadam
Presentation Type: Oral
Subject: Posterior Segment and Uveitis
Others:
Presenting Author:
Name: Ramin Nourinia
Affiliation :(optional) Ophthalmic research center, shahid beheshti university of medical science
E mail: ramin.retin@gmail.com
Phone: 04413365316
Mobile: 09128249332
Purpose:

To compare the efficacy of combined intravitreal bevacizumab and fasudil (IVB/IVF) with that of IVB alone for diabetic macular edema (DME).

Methods:

In this double masked randomized clinical trial study, 42 eyes with center involving DME were randomized to the two groups. The combined group (IVB/IVF) received 3 monthly injections of IVB (1.25 mg) and IVF (50 µM/L), while the IVB group received 3 monthly IVB (1.25 mg) injections. Findings of the best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between the two groups at 3 and 6 months of follow up.

Results:

Mean baseline CMT in the IVB/IVF group was 543±102μm which was decreased to 373±100μm and 356±119μm at months 3 and 6, respectively (P<0.001, for both times). Corresponding figures for the IVB group were 511±96μm, 439±112μm (P<0.001) and 509±120μm (P=0.738). CMT reduction was observed in both groups at month 3, but persisted up to 6 months only in the IVB/IVF group. CMT reduction was significantly greater in the IVB/IVF group at both time points (P<0.001). BCVA changes were consistent with CMT changes.

Conclusion:

Adjunctive intravitreal injection of a Rho-kinase inhibitor seems to enhance and prolong the effect of bevacizumab for DME.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        صفحه شخصی
        جستجوی سخنران
        آرشیو کنگره سالهای گذشته
 
ورود شرکت کنندگان
نام کاربری :
کلمه عبور :
  کلمه عبور خود را فراموش کرده ام.
Total Visits
Find us on Social Media
Congress Count Down
Today Label
Last Month Label
Total Visitors Label